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Fanconi anemia is rare inherited disease characterized by wide spectrum of congenital 
anomalies, progressive pancytopenia, and predisposition to hematological malignancies 
and solid tumors. Molecular genetic analysis of mutations in FANC genes is of a great 
importance for diagnosis confirmation, prenatal and carrier testing, as well as for 
prediction of chemotherapy outcome and disease complications. In this study we 
performed screening of frequently affected regions of FANCD2 gene for sequence 
variants in six unrelated FA-D2 patients in Serbia. This is the first molecular analysis of 
FANCD2 gene in Serbian FA-D2 patients. A total of 10 sequence variants were detected, 
one in homozygous, and nine in heterozygous state. Two variants were found within 
exons, and eight within introns, in deep intronic regions. In-silico analysis showed that 
among all detected variants one exon variant and three intron variants might have impact 
on splicing mechanism. Heterozygous variants found in intron 3, c.206-246delG; exon 26, 
c.2396 C>A and intron 28, c.2715+573 C>T were not previously reported. In-silico 
analysis revealed that among them, two (intron 3, c.206-246 delG and exon 26, c.2396 
C>A) could be novel disease-causing mutations. Many variants were found in more than 
one patient, including those unreported, indicating their possible ethnic association. Great 
number of variants in some patients suggests their non-random emergence in Fanconi 
anemia pathway.  
Keywords: deep intronic variants, Fanconi anemia, FANCD2 variants, splicing 
mechanism 
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LIST OF ABBREVIATIONS 
∆CV – Delta Consensus Value; ALL – Acute Lymphoblastic Leukemia; BLAST – Basic Local 
Alignment Search Tool; BMF – Bone Marrow Failure; BRCA – Breast Cancer Gene; dbSNP – 
Database of Single Nucleotide Polymorphisms; DEB – Diepoxybutane; FA – Fanconi Anemia; 
FANCD2 – Fanconi Anemia Complementation group D2; HGVS – Human Genome Variation 
Society; HSF – Human Splicing Finder; LRG – Locus Reference Genomic; MMC – Mitomycin C; 
NCBI – National Center for Biotechnology Information; PAA – Polyacrylamide; 
wt – Wild type 
 
INTRODUCTION 
Fanconi anemia (FA) is a rare inherited disease characterized by wide spectrum of 
congenital anomalies, progressive pancytopenia which often leads to bone marrow failure (BMF), 
and predisposition to hematological malignancies and solid tumors (SOULIER, 2011). Biallelic 
mutations in any of 19 up so far described FA genes, FANCA to FANCT (DONG et al,. 2015), 
which are a part of FA/BRCA DNA damage repair pathway lead to development of a 
corresponding complementation group (FA-A to FA-T complementation groups) of Fanconi 
anemia. In Serbia the most frequent complementation group is FA-D2 (VUJIC et al., 2014), 
whereas in the world population it accounts between 1% and 3.3% (LEVITUS et al., 2004; KALB et 
al., 2007) of all FA patients. 
The diagnostic approach for FA includes, besides physical examination, analysis of 
cellular sensitivity to DNA cross-linking agents such as diepoxybutane and mitomycin C (DEB 
and MMC) (AUERBACH, 2009) and determination of FA complementation group by 
immunoblotting (SHIMAMURA et al., 2002). Molecular analysis of germ-line mutation is of a great 
importance for diagnosis confirmation, prenatal and carrier testing, as well as for prediction of 
chemotherapy outcome (BORRIELLO et al., 2007). Additionally, even monoallelic mutations of a 
certain FA genes, such as FANCD2, are associated with the greater risk of developing 
hematological and solid tumors, such as T-cell acute lymphoblastic leukemia (ALL) and testicular 
seminoma (SMETSERS et al., 2012), which makes the molecular analysis important for evaluation 
of disease complications. 
Mutation analysis can be difficult considering the size of FA genes and existence of 
pseudogenes. FANCD2 gene (Locus Reference Genomic, LRG_306) is located on the short arm of 
the chromosome 3, 3p25.3 (TIMMERS et al., 2001). This gene is highly conserved in eukaryotic 
organisms, confirming its’ important role in DNA damage repair.  It contains 44 exons with the 
start codon localized in exon 2, and spans approximately 75.5 kb. Mutational analysis is hindered 
due to the existence of two known unprocessed pseudogenes, FANCD2-P1 (NCBI Acc. No. 
NG_025673.2) located upstream of FANCD2 and spanning 16 kb, and FANCD2-P2 (NCBI Acc. 
No. XM_017030238.1) located downstream of FANCD2 and spanning approximately 31.5 kb. 
Both pseudogenes show high percentage of sequence homology with the front (FANCD2-P1) and 
the middle portion (FANCD2-P2) of the FANCD2 gene, which makes primer construction for 
specific gene amplification difficult to achieve. Therefore, despite the development of new 
technologies, there is limited number of reports regarding FANCD2 mutations (KALB et al., 2007; 
AMEZIANE et al., 2012; KNIES et al., 2012; GILLE et al., 2012; CHANDRASEKHARAPPA et al., 2013; 
CHANG et al., 2014). Studies considering FANCD2 mutations in FA-D2 patients showed 
hypomorphic nature of the mutations since the residual FANCD2 protein with a preserved function 
was always present as showed by immunoblotting (KALB et al., 2007). Additionally, Kalb and 
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coworkers in their extensive study showed that more than a half of mutated alleles reside within 
introns and result in aberrant splicing; many mutations are recurrent and have ethnic association.  
The aim of this study was to screen frequently affected regions of FANCD2 gene for 
sequence variants in FA-D2 patients from Serbia. This is the first molecular analysis of FANCD2 
gene in Serbian FA-D2 patients. 
 
MATERIALS AND METHODS 
Patients  
A total of 6 unrelated FA-D2 patients were included in this study. Diagnosis of FA was 
previously confirmed by a positive DEB test, Western blot analysis and correction of cellular 
phenotype with particular FANC genes (AUERBACH, 2009; SHIMAMURA et al., 2002), and an 
assignment to FA-D2 complementation group was previously reported (JOKSIC et al., 2012; VUJIC 
et al., 2014). This study was approved by The Ethical Committee of the Mother and Child Health 
Care Institute of Serbia „Dr Vukan Cupic“. 
 
DNA isolation, PCR and sequencing 
Total DNA was isolated from patients’ fibroblast cells using FlexiGene DNA Kit 
(Qiagen) according to the manufacturer instructions. The regions with frequently described 
mutations were screened for mutations. Amplification was performed using Phusion High Fidelity 
PCR Kit (Thermo Scientific). Primers used for the amplification of the target regions are shown in 
the Table 1. Primers for exons 10, 16, 26, 29 and 38 as well as for the amplicon I were used 
according to Kalb and coworkers (KALB et al., 2007). Primers for exon 14, introns 3, 4, 12, 21 and 
28 as well as for the amplicon II were designed using Primer3Plus software. Sequences of the gene 
and the pseudogenes were previously aligned (NCBI BLAST, ClustalW) and regions that do not 
share homology were identified for placing the primers. Since introns 12 and 21 have high 
homology with pseudogenes, two large superamplicones (amplicon I and II) were generated by 
primers positioned in flanking region (region without homology with pseudogenes; from this 
amplicons introns 12 and 21 were reamplified, respectively (Nested PCR)). Two pairs of primers 
were used for amplification of introns 3 and 28 due to their great length.  
All primers were blasted against the whole genome for specificity. PCR products were 
purified using QIAquick kit (Qiagen) according to the manufacturer instructions and checked on 
the silver stained polyacrylamide (PAA) gels. The sequencing was performed on ABI 3730 
capillary genetic analyzer, Applied Biosystems (Macrogen, Netherlands, Europe).  
 
Sequence analysis 
NCBI BLAST (www.ncbi.nlm.nih.gov/BLAST/) was used for homozygous variation 
detection, and FinchTV and DNA Tools Xplorer softwares were used for the heterozygous 
variation analysis. Designation of FANCD2 variations was performed according to Human 
Genome Variation Society (HGVS) recommendations, Genome Reference Consortium Human 
Build 38 patch release 2 (GRCh38.p2 assembly), and Ensembl variation database. All found 
variants were checked in the currently available databases for reported mutations and single 
nucleotide polymorphisms (SNPs). 
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Table 1. FANCD2 exon, intron and amplicon primers 
FANCD2 regions Primer sequence (5’- 3’) Annealing temperature (⁰C) 
FANCD2 intron 3(1) 
 
F: AGGAAGCAACCACTTTCCAA 
R: GACCTGCCATAACCTTAGCAA 
60⁰C 
FANCD2 intron 3(2) 
 
F: TGTTTTGGGGGAGCAGATTA 
R: GGGATAGGAAGGGTGTCTCC 
56⁰C 
FANCD2 intron 4 
 
F: AGACACAACCCCATGACTCTG 
R: GCAGACGCTCACAAGACAAA 
60⁰C 
FANCD2 exon 10 
 
F: GCCCAGCTCTGTTCAAACCA 
R: CATTACTCCCAAGGCAATGAC 
65⁰C 
FANCD2 intron 12 
 
F: CTGGACTGTGCCTACCCACT 
R: TCAGCGAAACACGTTACACC 
60⁰C 
FANCD2 exon 14 
 
F: GTTGCCAGATGGACACATTG 
R: GACCTGGCTTCTTTGACTGC 
65⁰C 
FANCD2 exon 16 
 
F: AGGGAGGAGAAGTCTGACATT 
R: TTCCCCTTCAGTGAGTTCCAA 
65⁰C 
FANCD2 intron 21 
 
F: GCAGATTGGAAAAGGGATGA 
R: CTACGAAGGCATCCTGGAAA 
65⁰C 
FANCD2 exon 26 
 
F: GACATCTCTCAGCTCTGGATA 
R: TCAGGGATATTGGCCTGAGAT 
65⁰C 
FANCD2 intron 28(1) 
 
F: ATGTGACCCTACGCCATCTC 
R: AGCTTAGGGGCCAGAATGAT 
58⁰C 
FANCD2 intron 28(2) 
 
F: TTCTGTAAGAGCCCAAGTTTCA 
R: ACCTCAATGTCCAGCTCTCG 
60⁰C 
FANCD2 exon 29 
 
F: CTTGGGCTAGAGGAAGTTGTT 
R: TCTCCTCAGTGTCACAGTGTT 
65⁰C 
FANCD2 exon 38 
 
F: GCACTGGTTGCTACATCTAAG 
R: AAGCCAGGACACTTGGTTTCT 
65⁰C 
FANCD2 amplicon I 
 
F: TGCTCTTCTCTGTCCCCAGA 
R: CATTGGGCGTGTATTCAGGG 
58⁰C 
FANCD2 amplicon II 
 
F: GCTTCTAGTCACTGTCAGTTCACCAG 
R: ACGTTGGCCAGAAAGTAATCTCAG 
60⁰C 
 
In-silico analysis  
FANCD2 variants, especially those found in intronic regions and not previously reported, 
were further evaluated for the potential effect on the splicing. Human splicing finder, HSF 
(http://www.umd.be/HSF3/) was used for the prediction of the intronic variants effects on the 
splicing mechanism. Pathogenicity of the exonic variants that lead to amino acid substitutions, was 
assessed via PolyPhen2 (http://genetics.bwh.harvard.edu/pph2/) program.  
 
RESULTS  
Of all regions of FANCD2 gene that have been screened in patients, a total of 10 
sequence variants were found. Table 2 summarizes all detected variants and a predicted 
consequence, if known, in the currently available databases. Most of the nucleotide changes were 
found at the heterozygous state, except for one found in all patients in intron 12 at homozygous 
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state (c.990-133 G>T), however this variant is commonly present in the healthy population, and 
has no clinical impact. In-silico analysis predicted that among all variants found, four (intron 3, 
c.206-246delG; intron 12, c.990-38 C>G; intron 28, c.2716-306 A>G; and exon 14, c.1122 A>G) 
might lead to the generation of the new splice sites. Heterozygous variants found in intron 3, 
c.206-246delG; exon 26, c.2396 C>A and intron 28, c.2715+573 C>T were not previously 
reported. 
 
Table 2. Detected FANCD2 variants, frequencies and predicted effects  
Region of 
FANCD2 
gene 
Genomic 
position 
(GRCh38.p2, 
Current 
assembly) 
Human 
Genome 
Variation 
Society 
nomenclature 
Frequency of 
allele in 
general 
population/ 
European 
population  
(HapMap) 
Frequency of 
genotype in 
general 
population/ 
European 
population 
 (HapMap) 
Homozygous/ 
Heterozygous 
Predicted 
effect on 
protein 
function 
Case 
number 
Ensembl 
variation 
database 
name 
(dbSNP) 
Intron 3 g.10034223 
delG 
c.206-246 
delG  
- - Heterozygous 
 
Not 
previously 
reported, 
creation of a 
new acceptor 
splicing site  
1 
2 
4 
 
- 
Intron 12 g.10043351 
G>T 
c.990-133 
G>T 
0.952/0.913 0.089/0.171 Homozygous 
T/T 
Intron variant 1 
2 
3 
4 
5 
6 
rs803335 
 
Intron 12 g.10043446 
C>G 
c.990-38 C>G 0.212/0.139 0.284/0.235 Heterozygous 
C/G 
Intron 
variant, 
creation of a 
new acceptor 
or donor 
splicing site 
1 
4 
rs9809061 
 
Exon 14 g.10043852 
A>G 
c.1122 A>G ?/0.034 ?/0.067 Heterozygous 
A/G 
Protein 
coding 
sinonimous 
variant, 
creation of a 
new donor 
splicing site 
1 
2  
4 
6 
rs34046352 
 
Intron 14 g.10043940 
G>T 
c.1134+76 
G>T 
 0.300, small 
sample 
0.600, small 
sample 
Heterozygous  
G/T 
Intron variant 1 
2 
4 
6 
 
rs35870071 
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Table 2. continued 
Region of 
FANCD2 
gene 
Genomic 
position 
(GRCh38.p2, 
Current 
assembly) 
Human 
Genome 
Variation 
Society 
nomenclature 
Frequency of 
allele in 
general 
population/ 
European 
population  
(HapMap) 
Frequency of 
genotype in 
general 
population/ 
European 
population 
 (HapMap) 
 
Homozygous/ 
Heterozygous 
Predicted 
effect on 
protein 
function 
Case 
number 
Ensembl 
variation 
database 
name 
(dbSNP) 
Intron 16 g.10048089 
A>C 
c.1413+38 
A>C 
0.179/0.139 0.272/0.235 Heterozygous  
A/C 
Intron 
variant and 
non coding 
transcript 
variant 
(retained 
intron) 
4 
6 
rs7615646 
 
Intron 21 g.10064163 
A>G 
c.1948-
193A>G 
0.026/0.070 0.049/0.131 Heterozygous  
A/G 
Intron 
variant and 
nonsense 
mediated 
decay 
transcript 
variant 
 
1  
2 
5 
 
rs2347585 
 
Exon 26 g.10067219 
C>A 
c.2396 C>A - - Heterozygous 
C/A 
p.A799D  2 
5 
 
- 
Intron 28 g.10074250 
C>T 
c.2715+573 
C>T 
- - Heterozygous 
C/T 
Unknown, 
not 
previously 
reported  
1 
2 
4 
6 
 
- 
Intron 28 g.10074224 
A>G 
c.2716-306 
A>G 
0.001/0.002 0.002/0.004 Heterozygous  
A/G 
Intron 
variant, 
creation of a 
new donor 
splicing site  
2 rs19280430
3 
 
*Bold variants are not found in the currently available databases. 
The Ensembl Variation database  
The Short Genetic Variations database (dbSNP) (NCBI dbSNP database) 
Fanconi anemia mutation database 
 
 
J.FILIPOVIC TRICKOVIC et al: FANCD2 GENOTYPES OF FANCONI ANEMIA PATIENTS IN SERBIA           565 
Exon variants 
Two sequence variants in exons were found, heterozygous variant in exon 26, c.2396 
C>A, and heterozygous variant in exon 14, c.1122 A>G whereas all other changes were detected 
within deep intronic regions.  
Bioinformatics analysis of genomic variant in exon 26, c.2396 C>A (Figure 1) which was 
found in heterozygous state in two patients (cases 2 and 5) showed that this is probably damaging 
missense mutation p.A799D (PolyPhen2, score - 0.99). This variant has not been previously 
reported. 
Genomic variant in exon 14, c.1122 A>G was found in four patients in heterozygous state 
(cases no 1, 2, 4 and 6). This variant was reported in dbSNP - rs34046352, and referred as “protein 
coding synonymous variant”, but experimental data on its function was not available. In-silico 
analysis of this variant using HSF predicted activation of an exonic cryptic donor site with 
potential alteration of splicing (HSF scores: wild type (wt) – 40.32, mutant – 67.16, delta 
consensus value (∆CV) – 66.57%). 
 
 
 
Figure 1. Sequencing chromatogram of FANCD2 variant in exon 26, c.2396 C>A. Arrow indicates the 
presence of two peaks on the position c.2396 of FANCD2 gene. 
 
 
Intron variants 
Eight sequence variants were detected within intronic regions, many of which have been 
reported in databases (Table 2). Among all found intronic variants, in-silico analysis showed that 
three variants (intron 3, c.206-246 delG; intron 12, c.990-38 C>G and intron 28, c.2716-306 A>G) 
might have impact on splicing mechanism.  
Unreported variant in intron 3, c.206-246delG which is found in three patients (cases 1, 2 
and 4) is predicted to generate a new acceptor splicing site (Figure 2), upstream to the 
physiological acceptor splice site to the exon 4, with a very high score, according to HSF (HSF 
scores: wt – 10.13, mutant – 77.24, ∆CV – 662.49%). Creation of a new acceptor splicing site was 
also predicted for the intronic variant in intron 12, c.990-38 C>G, found in two patients (cases 1 
and 4), upstream to the physiological splice site to the exon 13 (HSF scores: wt – 56.61, mutant – 
85.55, ∆CV – 51.12%). This variant was previously reported in dbSNP (rs9809061), however its 
effect was not assessed.  
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Variant detected in intron 28, c.2716-306 A>G is predicted to generate a new donor 
splicing site downstream to the physiological donor splice site (HSF scores: wt – 40.04, mutant – 
66.87, ∆CV – 67.01%). Although reported in dbSNP - rs192804303, the presence of this variant is 
rather low in the world and European population - 0.001, and its functional significance is not 
assessed. 
 
 
Figure 2. Sequencing chromatogram of FANCD2 variants in intron 3, c.206-246delG. Blue vertical lines 
indicate position where the deletion has occurred; chromatogram of the control sample (A), 
heterozygous indel (B) and heterozygous deletion (C) in affected patient are presented. Double peaks 
after deletion can be observed (C). 
 
Distribution of FANCD2 genomic variants among patients 
As seen in Table 3, in patient 3 only one variant was detected (common variant in intron 
12 in homozygous state, also detected in all other patients). In all other patients three or more 
variants were found, whereas in three patients (1, 2, and 4) up to eight variants were detected. 
According to the prediction results (mutant scores <70 were considered ambiguous and therefore 
irrelevant without further investigation), in patients 1, 2 and 4 two pathogenic variants were found.  
In patient 5 only one pathogenic variant was found, whereas in patients 3 and 6 none of 
the genomic variants detected is predicted to be a disease causing.  
In-silico analysis revealed that among three previously unreported variants, two (intron 3, c.206-
246 delG and exon 26, c.2396 C>A) could be novel disease causing mutations. 
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Table 3. Unreported and reported FANCD2 variants in FA-D2 patients 
 FANCD2 variants (according to Human Genome Variation Society nomenclature) 
 
Case number Unreported variants Variants with low frequencies <1% Variants with frequencies >1% 
1 
 
c.206-246 delG 
  
c.2715+573 C>T 
 
- 
 
c.990-133 G>T 
 
c.990-38 C>G 
 
c.1134+76 G>T 
 
c.1948-193A>G 
 
c.1122 A>G 
2 
 
c.206-246 delG  
 
c.2715+573 C>T 
 
c.2396 C>A 
 
 
c.2716-306 A>G 
c.990-133 G>T 
 
c.1134+76 G>T  
 
c.1948-193A>G 
 
 c.1122 A>G 
3 
 
- - c.990-133 G>T 
4 
 
c.2715+573 C>T 
 
c.206-246 delG  
 
 
 
 
 
 
- c.990-133 G>T 
 
c.990-38 C>G 
 
c.1134+76 G>T 
 
c.1413+38 A>C  
 
c.1122 A>G 
5 
 
c.2396 C>A - c.990-133 G>T 
 
c.1948-193A>G 
6 
 
c.2715+573 C>T - c.990-38 C>G 
c.1122 A>G 
 
c.1134+76 G>T 
 
c.1413+38 A>C 
 
DISCUSSION 
The analysis of particular FANCD2 regions in FA-D2 patients in Serbian population 
revealed ten genomic variants, three of which have not been previously reported. One novel 
missense mutation found in two patients in exon 26, c.2396 C>A leads to the substitution of 
alanine with aspartic acid at the position 799 (p.A799D). According to the prediction program 
PolyPhen2, this mutation is pathogenic and could lead to partial degradation of protein. Another 
novel genomic variant c.206-246delG detected in intron 3 in three patients is predicted to affect 
splicing, i.e. creates a new acceptor splicing site 246 nt upstream to the physiological splicing site 
and may lead to intronic exonisation.  
Additionally, among other detected variants which have already been reported to the 
dbSNP, prediction tools revealed that three could influence the splicing pattern of FANCD2 gene. 
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Even though reported, the frequency of these variants is low in the population (Table 2), and their 
functional significance has not been assessed. Creation of an aberrant acceptor splicing site was 
estimated for the variant in intron 12, c.990-38 C>G, upstream to the physiological splicing site for 
the exon 13. Despite the fact that this variant is reported in the dbSNP (rs9809061), its 
pathogenicity has not been determined. It is important to mention that known SNPs, as well as 
synonymous mutations can also lead to the disease, and requires further investigation (CHANG et 
al., 2014; CHANDRASEKHARAPPA et al., 2013), therefore they cannot be excluded as variants 
related to FA disease. Both of these variants (intron 3, c.206-246delG and intron 12, c.990-38 
C>G) anticipated to create alternative splicing sites have high prediction scores for the mutant 
allele, scores below the threshold for the wt allele and high delta between the wt and the mutant 
CV (Table 4), suggesting great probability of creation of the splice sites in intronic regions where 
splicing normally doesn’t occur. According to Desmet and coworkers in their detailed and 
comprehensive study including 83 intronic and 35 exonic mutations known to cause aberrant 
splicing, HSF was able to correctly predict the effects of these mutations with very high 
sensitivity, especially for intronic mutations with such high scores (DESMET et el., 2009). 
Additionally, studies which included in-silico and functional analysis showed that HSF is the most 
reliable and informative prediction software (NASCIMBENI et al., 2010). 
Two variants of unknown significance reported in the dbSNP were predicted to create 
alternative donor splicing sites, intron 28, c.2716-306 A>G and exon 14 c.1122 A>G 
(rs192804303 and rs34046352, respectively). The variant in intron 28 is found with very low 
frequency in the world and European population (0.001 and 0.002, respectively; data from 1000 
genomes and HapMap project) and the effects of this variant are not known. Variant in exon 14 is 
reported as protein coding synonymous variant, but without experimental data of its pathogenicity. 
Nowadays it is known that synonymous and silent mutations can lead to modification of protein 
conformation and function, so despite once considered harmless, their importance in human 
diseases is widely accepted (CHAMARY et al., 2006). Albeit both of these variants (intron 28, 
c.2716-306 A>G and exon 14 c.1122 A>G) were estimated to create a new donor splicing site by 
HSF, mutant scores were slightly above the threshold values, and are therefore considered 
ambiguous without further functional analysis.     
Recent studies focused on identifying disease causing mutations in FANCD2 gene 
pointed out the hypomorphic and heterogeneous nature of found mutations. Apparently, 
homozygous mutations in FANCD2 are rather rare, but compound heterozygous mutations are 
mostly found. Furthermore, the great majority of reported mutations were found within intronic 
regions, near the exon-intron boundary or in deep intronic regions (KALB et al., 2007; 
CHANDRASEKHARAPPA et al., 2013; AMEZIANE et al., 2012). Presence of missense mutation which 
leads to FANCD2 protein with altered activity and intronic mutations which can cause aberrant 
splicing is consistent with the fact that residual amount of FANCD2 is present in all FA-D2 
patients.  
Detection of same variants, which are predicted to be pathogenic, in several unrelated 
patients (Table 2), such as intron 3, c.206-246 delG in three patients, exon 14, c.1122 A>G, in four 
patients and exon 26, c.2396 C>A in two patients suggests that these variants could be population-
specific and due to the founder effect of ancestral allele. Kalb and colleagues also found that some 
FANCD2 mutations are highly specific for the patients’ origin, such as splice mutation in intron 
21, c.1948-16 T>G which is strongly related to the Turkish origin (KALB et al., 2007). Association 
of specific mutations with the certain populations was also found in other FA genes (MADJUNKOVA 
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et al., 2014; TIPPING et al., 2001). Variants in intron 3, c.206-246 delG and exon 26, c.2396 C>A, 
found in this study, were not previously reported, even though large-scale studies on FA-D2 
patients from multiple populations have been performed, indicating their possible linkage to the 
Serbian population.  
Another interesting finding in our study is that in three patients (cases 1, 2 and 4), up to 
eight FANCD2 variants were found, whether assessed to be pathogenic or not (Table 2 and 3). As 
proposed by Chang and colleagues (CHANG et al., 2014), high frequency of heterozygous variants 
suggests that mutations doesn’t occur randomly, but might be linked and reflect the susceptibility 
of FA pathway, or in this case FANCD2 gene. They found a great number of concomitant 
mutations in FA patients, and not only in one gene, but throughout the FA pathway genes, which 
implies that assignment to some FA complementation group doesn’t exclude mutations in other 
FANC genes. Knies and colleagues (KNIES et al., 2012) also pointed out that single heterozygous 
mutation in one FA gene may be accompanied by the heterozygous mutation in other FA genes 
and lead to the disease. Our previous detailed molecular-cytogenetic investigation of these patients 
showed that cases 1 and 2 in which 7 and 8 variants were found, respectively, developed, at the 
time of sampling, severe BMF, had shorter telomeres, more telomere fusions and radial figures and 
different chromosomal breakage pattern compared to other FA-D2 patients (JOKSIC et al., 2012; 
FILIPOVIC et al., 2016). This is consistent with Chang’s statement that great number of variants 
reflects the susceptibility of FA pathway.  
Comparing the results obtained by Sanger sequencing and in-silico analysis showed that 
only in two patients, potentially pathogenic mutation was not detected, whereas in one patient only 
one pathogenic variant was found, in examined DNA regions. However, we only did screening for 
certain commonly affected FANCD2 regions, so the disease-causing mutation could be in other 
FANCD2 regions, or in the form of a large deletion/insertion, which could not be detected by 
sequencing techniques. We are aware that in examined patients’ cohort, which is rather small, 
further analyses are required, such as next generation sequencing and whole exome sequencing 
(NGS and WES) for complete coverage and multiple ligation-dependent probe amplification 
(MLPA) and microarray techniques for the large mutations detection (GILLE et al., 2012; CHANG et 
al., 2014; CHANDRASEKHARAPPA et al., 2013). NGS and WES could provide greater coverage; 
however, deep intronic mutations are not detectable by WES (KNIES et al., 2012). Additionally, the 
presence of two FANCD2 pseudogenes can lead to the incorrect mapping of the variants by NGS 
and WES (KNIES et al., 2012), which still makes these methods insufficiently reliable and 
requires confirmation by Sanger sequencing.  
Summarized, we found three novel, yet unreported variants in FANCD2 gene, two of 
which could be novel disease-causing mutations. Except one, all variants were present in 
heterozygous state, whereas the majority was found in deep intronic regions. Many of the detected 
variants were found in more than one patient, including those unreported, indicating their possible 
ethnic association. Finding of a great number of variants in some patients suggests their non-
random occurrence in susceptible FA pathway.  
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Izvod 
Fankonijeva anemija (FA) predstavlja retko nasledno oboljenje koje karakteriše širok spektar 
kongenitalnih anomalija, progresivna pancitopenija i sklonost ka razvoju hematoloških maligniteta 
i solidnih tumora. Molekularno genetička analiza mutacija u FANC genima je veoma značajna za 
potvrdu dijagnoze oboljenja, prenatalno i testiranje nosioca, kao i predikciju ishoda hemoterapije i 
komplikacija oboljenja. Ispitivali smo prisustvo varijanti u često izmenjenim regionima gena 
FANCD2 (6 egzona i 5 introna) kod 6 FA-D2 pacijenata u Srbiji metodom Sangerovog 
sekvenciranja. Ovo je prva molekularna analiza FANCD2 gena kod FA-D2 pacijenata u Srbiji.  
Detektovano je ukupno 10 varijanti, jedna homozigotna i 9 heterozigotnih, od toga dve u 
egzonima, a 8 u dubokim intronskim regionima. In-silico analiza je pokazala da od svih 
detektovanih varijanti jedna egzonska i tri intronske mogu uticati na “splajsing”. Heterozigotne 
varijante u intronu 3, c.206-246delG; egzonu 26, c.2396 C>A i intronu 28, c.2715+573 C>T nisu 
prethodno prijavljene. In-silico analiza je pokazala da dve među njima (intron 3, c.206-246 delG i 
egzon 26, c.2396 C>A) mogu biti nove mutacije koje uzrokuju bolest. Mnoge varijante su 
detektovane kod više od jednog pacijenta, uključujući neprijavljene, što bi moglo ukazivati na 
etničku asocijaciju. Veliki broj varijanti kod nekih pacijenata ukazuje na njihovu ne-nasumičnu 
pojavu u putu FA.   
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